Literature DB >> 7247369

Pharmacokinetics of cefuroxime in normal and impaired renal function: comparison of high-pressure liquid chromatography and microbiological assays.

R W Bundtzen, R D Toothaker, O S Nielson, P O Madsen, P G Welling, W A Craig.   

Abstract

The pharmacokinetics of cefuroxime were studied after a single dose of 750 mg was given intravenously to each of 21 male volunteers grouped according to their creatinine clearances; these clearances were 60 to 120, 20 to 59, and less than 20 ml/min per 1.73 m,2 respectively, for groups 1 (12 subjects), 2 (4 subjects), and 3 (5 subjects). Cefuroxime obeyed two-compartment model kinetics in all three groups. Initial serum levels of cefuroxime were approximately 130 microgram/ml in group 1 and 2 and 80 microgram/ml in group 3. the levels then declined rapidly for 0.5 to 1 h after injection. After that time, cefuroxime levels declined more slowly, and the elimination rate became monoexponential. The mean serum half-lives for cefuroxime in groups 2, 2, and 3 were 1.7, 2.4, and 17.6 h, respectively. Mean cefuroxime levels in serum were greater than 8 microgram/ml for 3 h in group 1, for 6 h in group 2, and for 30 h in group 3. Cumulative 24-h urinary excretion accounted for essentially 100% of the dose in group 1 and 2, and for 40% in group 3. Urine levels exceeded the minimal inhibitory concentration for susceptible organisms for more than 12 h in all groups. Cefuroxime distribution characteristics were independent of renal function. In patients with creatinine clearances less than 20 ml/min per 1.73 m2, doses of cefuroxime needs to be reduced. A microbiological disk diffusion assay and a high-pressure liquid chromatography assay for cefuroxime yielded statistically identical results, except for serum levels in uremic patients (group 3).

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7247369      PMCID: PMC181451          DOI: 10.1128/AAC.19.3.443

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

1.  The effect of Renal Failure and Dialysis on the Pharmacokinetics of Cefuroxime.

Authors:  P E Gower; M R Kennedy; C H Dash
Journal:  Proc R Soc Med       Date:  1977

2.  Phase one clinical study on cefuroxime.

Authors:  K Nakagawa
Journal:  Proc R Soc Med       Date:  1977

3.  Cefuroxime, a beta-lactamase-resistant cephalosporin with a broad spectrum of gram-positive and -negative activity.

Authors:  H C Neu; K P Fu
Journal:  Antimicrob Agents Chemother       Date:  1978-04       Impact factor: 5.191

4.  Clinical and pharmacokinetic studies on cefuroxime.

Authors:  R Norrby; R D Foord; P Hedlund
Journal:  J Antimicrob Chemother       Date:  1977-07       Impact factor: 5.790

5.  Cefuroxime, a new parenteral cephalosporin: collaborative in vitro susceptibility comparison with cephalothin against 5,887 clinical bacterial isolates.

Authors:  R N Jones; P C Fuchs; T L Gavan; E H Gerlach; A L Barry; C Thornsberry
Journal:  Antimicrob Agents Chemother       Date:  1977-07       Impact factor: 5.191

6.  Pharmacokinetics of cefamandole using a HPLC assay.

Authors:  N S Aziz; J G Gambertoglio; E T Lin; H Grausz; L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1978-04

7.  Determination of plasma and renal clearance of cefuroxime and its pharmacokinetics in renal insufficiency.

Authors:  R van Dalen; T B Vree; J C Hafkenscheid; J S Gimbrère
Journal:  J Antimicrob Chemother       Date:  1979-05       Impact factor: 5.790

8.  Cefuroxime, a new cephalosporin antibiotic: activity in vivo.

Authors:  D M Ryan; C O'Callaghan; P W Muggleton
Journal:  Antimicrob Agents Chemother       Date:  1976-03       Impact factor: 5.191

9.  Cefuroxime, a new cephalosporin antibiotic: activity in vitro.

Authors:  C H O'Callaghan; R B Sykes; A Griffiths; J E Thornton
Journal:  Antimicrob Agents Chemother       Date:  1976-03       Impact factor: 5.191

10.  Antibacterial activity of cefuroxime, a new cephalosporin antibiotic, compared with that of cephaloridine, cephalothin, and cefamandole.

Authors:  S Eykyn; C Jenkins; A King; I Phillips
Journal:  Antimicrob Agents Chemother       Date:  1976-04       Impact factor: 5.191

View more
  12 in total

1.  Modification of the pharmacokinetics and dosage of cefuroxime by endotoxin-induced fever in buffalo calves.

Authors:  R K Chaudhary; A K Srivastava; S Rampal
Journal:  Vet Res Commun       Date:  1999-10       Impact factor: 2.459

2.  High pressure liquid chromatographic analysis of the serum concentration of cefuroxime after an intravenous bolus injection of cefuroxime in patients with a coronary artery bypass grafting.

Authors:  M J Koot; F N IJdenberg; R M Stuurman; J Poell; L J Bras; J J Langemeijer; L Lie-A-Huen
Journal:  Pharm Weekbl Sci       Date:  1992-12-11

3.  Assessment of cefazolin and cefuroxime tissue penetration by using a continuous intravenous infusion.

Authors:  J E Connors; J T DiPiro; R G Hayter; K D Hooker; J A Stanfield; T R Young
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

4.  A population pharmacokinetic model for cefuroxime using cystatin C as a marker of renal function.

Authors:  Anders Viberg; Anders Lannergård; Anders Larsson; Otto Cars; Mats O Karlsson; Marie Sandström
Journal:  Br J Clin Pharmacol       Date:  2006-09       Impact factor: 4.335

5.  Transplacental transfer of cefuroxime in uncomplicated pregnancies and those complicated by hydrops or changes in amniotic fluid volume.

Authors:  D E Holt; N M Fisk; J A Spencer; J de Louvois; R Hurley; D Harvey
Journal:  Arch Dis Child       Date:  1993-01       Impact factor: 3.791

Review 6.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

Review 7.  Towards quantitation of the effects of renal impairment and probenecid inhibition on kidney uptake and efflux transporters, using physiologically based pharmacokinetic modelling and simulations.

Authors:  Vicky Hsu; Manuela de L T Vieira; Ping Zhao; Lei Zhang; Jenny Huimin Zheng; Anna Nordmark; Eva Gil Berglund; Kathleen M Giacomini; Shiew-Mei Huang
Journal:  Clin Pharmacokinet       Date:  2014-03       Impact factor: 6.447

Review 8.  Clinical pharmacokinetics of newer cephalosporins.

Authors:  M E Klepser; M N Marangos; K B Patel; D P Nicolau; R Quintiliani; C H Nightingale
Journal:  Clin Pharmacokinet       Date:  1995-05       Impact factor: 6.447

9.  Clinical on-site monitoring of ß-lactam antibiotics for a personalized antibiotherapy.

Authors:  R Bruch; C Chatelle; A Kling; B Rebmann; S Wirth; S Schumann; W Weber; C Dincer; G Urban
Journal:  Sci Rep       Date:  2017-06-09       Impact factor: 4.379

10.  Physiologically based pharmacokinetic evaluation of cefuroxime in perioperative antibiotic prophylaxis.

Authors:  Christer Rimmler; Christian Lanckohr; Ceren Akamp; Dagmar Horn; Manfred Fobker; Karsten Wiebe; Bassam Redwan; Bjoern Ellger; Robin Koeck; Georg Hempel
Journal:  Br J Clin Pharmacol       Date:  2019-12-15       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.